Loading...
Biological heterogeneity in hematologic malignancies is recognized clinically by differences in the potential for proliferation and dissemination and by disparate treatment responses. Efforts to categorize and better predict the biological activity and disease course of diffuse large B-cell lymphoma (DLBCL) led to gene expression profiling that identified germinal center (GC) and non-GC subtypes, which are associated with relatively better or poorer outcomes, respectively (N Engl J Med 2003; 348:1777). However, these subtype designations provide inconsistent prognostic information. To refine biomarkers with an eye toward stratifying DLBCL patients, investigators performed immunohistochemistry (IHC) and fluorescence in situ hybridization (FI…